

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 DECEMBER 2018

ERRATA

(1) This Erratum corrects the entry for VALSARTAN in the 1 December 2018 Schedule of Pharmaceutical Benefits as detailed below.

■ VALSARTAN

valsartan 40 mg tablet, 28

9368C	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
NP	1	16.23	17.46	^a APO-Valsartan [TX]	
			^B 2.15	18.38	17.46	^a Diovan [NV]	

valsartan 160 mg tablet, 28

9370E	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
NP	1	5	..	20.51	21.74	^a APO-Valsartan [TX]	
			^B 2.15	22.66	21.74	^a Diovan [NV]	

valsartan 80 mg tablet, 28

9369D	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
NP	1	5	..	18.48	19.71	^a APO-Valsartan [TX]	
			^B 2.15	20.63	19.71	^a Diovan [NV]	

■ VALSARTAN

Note No applications for increased maximum quantities and/or repeats will be authorised for the 320 mg tablet.

valsartan 320 mg tablet, 28

9371F	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
NP	1	5	..	23.10	24.33	^a APO-Valsartan [TX]	
			^B 2.15	25.25	24.33	^a Diovan [NV]	

(2) This Erratum corrects the entry for VALSARTAN + HYDROCHLOROTHIAZIDE in the 1 December 2018 Schedule of Pharmaceutical Benefits as detailed below.

▪ **VALSARTAN + HYDROCHLOROTHIAZIDE**

Restricted benefit

Hypertension

Clinical criteria:

- The treatment must not be for the initiation of anti-hypertensive therapy, **AND**
- The condition must be inadequately controlled with an angiotensin II antagonist; OR
- The condition must be inadequately controlled with a thiazide diuretic.

valsartan 160 mg + hydrochlorothiazide 25 mg tablet, 28

	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
9374J	1	5	..	21.66	22.89	^a APO-Valsartan HCTZ 160/25 [TX]	^a Co-Diovan 160/25 [NV]

valsartan 80 mg + hydrochlorothiazide 12.5 mg tablet, 28

	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
9372G	1	5	..	18.77	20.00	^a APO-Valsartan HCTZ 80/12.5 [TX]	^a Co-Diovan 80/12.5 [NV]

valsartan 160 mg + hydrochlorothiazide 12.5 mg tablet, 28

	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
9373H	1	5	..	20.58	21.81	^a APO-Valsartan HCTZ 160/12.5 [TX]	^a Co-Diovan 160/12.5 [NV]

▪ **VALSARTAN + HYDROCHLOROTHIAZIDE**

Note No applications for increased maximum quantities and/or repeats will be authorised for the tablets containing 320 mg valsartan.

Restricted benefit

Hypertension

Clinical criteria:

- The treatment must not be for the initiation of anti-hypertensive therapy, **AND**
- The condition must be inadequately controlled with an angiotensin II antagonist; OR
- The condition must be inadequately controlled with a thiazide diuretic.

valsartan 320 mg + hydrochlorothiazide 12.5 mg tablet, 28

	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
9481B	1	5	..	22.89	24.12	^a APO-Valsartan HCTZ 320/12.5 [TX]	^a Co-Diovan 320/12.5 [NV]

valsartan 320 mg + hydrochlorothiazide 25 mg tablet, 28

	Max.Qty Packs	No. of Rpts	Premium \$	DPMQ \$	MRVSN \$	Brand Name and Manufacturer	Brand Name and Manufacturer
9482C	1	5	..	23.96	25.19	^a APO-Valsartan HCTZ 320/25 [TX]	^a Co-Diovan 320/25 [NV]